You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY20 is not expected to be complete until September, 2021.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

  1. A New Drug Therapy for Advanced Heart Failure

    SBC: CORNOVUS PHARMACEUTICALS INC.            Topic: NHLBI

    PROJECT SUMMARY Current therapy for advanced heart failure (HF) is limited and new treatment is needed since the mortality and morbidity of subjects with this form of heart disease remain high. Effort aimed at enhanced healing of failing heart by cardioprotection represents a novel approach. The specific background for the proposed project is that we have identified the endogenous cardiac P2X rece ...

    SBIR Phase II 2020 Department of Health and Human ServicesNational Institutes of Health
  2. Development of TP-352 for the Treatment of Pediatric Non-alcoholic Steatohepatitis

    SBC: Thetis Pharmaceuticals LLC            Topic: 300

    ABSTRACTNon-alcoholic fatty liver disease (NAFLD) refers to a spectrum of diseases related to metabolic syndrome that are characterized by steatosis, the accumulation of fat within the liver. Non-alcoholic steatohepatitis (NASH), the most aggressive NAFLD subtype, refers to the presence of inflammation and necrosis in a background of steatosis, and is associated with hepatic fibrosis. NASH is a se ...

    SBIR Phase II 2020 Department of Health and Human ServicesNational Institutes of Health
  3. Amyloid Beta Oligomer Induction of Alzheimer Disease in Nonhuman Primates

    SBC: Virscio, Inc.            Topic: NIA

    PROJECT SUMMARY Patients with Alzheimer’s disease (AD) suffer a progressive loss of memory and cognitive ability, and eventual loss of basic bodily functions and death. The incidence and toll of AD on the healthcare system continues to rise with significant societal impact. There are no treatments for AD to prevent its inexorable course, and the principal obstacle to developing new therapies for ...

    SBIR Phase II 2020 Department of Health and Human ServicesNational Institutes of Health
  4. Clinical Evaluation of NoGo Trap Therapy in Chronic SCI

    SBC: ReNetX Bio, Inc.            Topic: NINDS

    Summary Approximately 300,000 patients suffer from persistent neurological impairment due to chronic spinal cord injury (SCI) in the United States. Currently, there are no FDA-approved drugs to promote neurologic recovery in patients suffering from the life-long, profound impairments due to chronic SCI. An effective neurorestorative therapy would significantly improve the ability of patients to co ...

    SBIR Phase II 2020 Department of Health and Human ServicesNational Institutes of Health
  5. An antigen-detection assay to diagnose Babesia microti infection

    SBC: L2 Diagnostics, LLC            Topic: NIAID

    PROJECT SUMMARY Human babesiosis is a malaria-like multisystem disease caused primarily by Babesia microti, an emerging apicomplexan parasite that infects and develops within human erythrocytes. The parasite is transmitted to humans by the tick vector Ixodes scapularis and can also be introduced through blood transfusion. Infection can cause flu-like symptoms, and severe infection can be fatal, in ...

    SBIR Phase II 2020 Department of Health and Human ServicesNational Institutes of Health
  6. Daily and Localized NSAID Sonophoresis for Symptomatic Treatment of Knee Osteoarthritis

    SBC: Zetroz Systems LLC            Topic: R

    Project Summary: Osteoarthritis (OA) is the most common type of arthritis, affecting over 30 million adults in the United States in 2015 and represents over 25% of medical office visits according to the Centers for Disease Control and Prevention and the National Institutes of Health. Over 40% of individuals over 65 have symptomatic OA and reduced mobility due to the disease. OA pain is often mitig ...

    SBIR Phase II 2020 Department of Health and Human ServicesNational Institutes of Health
  7. PAASPort: A web-based tool for nonclinical research quality assessment and risk of bias management to advance development of innovative medications

    SBC: PAASP US, LLC            Topic: NIDA

    PROJECT SUMMARY / ABSTRACTRobust nonclinical data is an absolute requirement for building an effective translational strategy and developing clinically safe and effective medications. Most current efforts to facilitate generation of robust nonclinical research data focus on producing guidelines and checklists pertaining to study design and data analysis, but: a) do so only from a reporting perspec ...

    SBIR Phase II 2020 Department of Health and Human ServicesNational Institutes of Health
  8. Development of tumor-targeted PARP inhibitors for the treatment of solid cancers

    SBC: Cybrexa, Inc.            Topic: 102

    PROJECT SUMMARY Monotherapy regimens of poly(adenosine diphosphate [ADP]) ribose polymerase inhibitor (PARPi) have demonstrated clear efficacy in the clinic against metastatic solid tumors, with the greatest activity observed in homologous recombination deficient HRD cancers, but have limited activity against non-HRD cancers. As such, there is great interest in combining PARPiandapos;s with other ...

    SBIR Phase II 2020 Department of Health and Human ServicesNational Institutes of Health
  9. TOPIC 366: I-PARTS INTEGRATED PLATFORM FOR ANTI-CANCER RADIATION THERAPEUTICS SCREENING

    SBC: PACT & HEALTH LLC            Topic: NCI

    Tumor Irradiation during cancer treatment induces clonogenic death that can be best assessed by colony forming assaysThese colony forming assays are laborious and never utilized in high throughput screeningHTSformatsWe propose to develop anintegrated platform for HTS clonogenic survival assayfor cancer drug screening as well as radiation effect modulation screeningNamedI PARTSIntegrated platform f ...

    SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  10. Measuring toxicant effects on cellular function in a microarray format

    SBC: CIENCIA INC            Topic: 113

    Project Summary/Abstract – The EPA maintains a Toxics Release Inventory of andgt;650 toxic chemicals that are disposed or released from andgt;20,000 industrial sites in the United States, while HHS and USDA maintain a list of over 60 select agents and toxicants that pose a severe risk to human, animal, and plant health. These compounds represent only a fraction of the known and unknown environme ...

    STTR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government